VivoSeq
Neurology

Focal-Onset Seizure

10

Pipeline Programs↗

2

Active Trials↗

8

Companies Involved↗

Focal-onset seizure is an early-stage landscape with 10 programs across 8 companies. The most active players are Jazz Pharmaceuticals, Xenon Pharmaceuticals Inc., Teva. 6 therapies are approved with 2 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

29/100

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

1 program

Phase 1X

Xenon Pharmaceuticals Inc.

1 program

Phase 3Teva logo

Teva

1 program

Phase 3V

Viatris Specialty LLC

1 program

ApprovedC

Catalyst Biosciences

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Terminated2 · 33%
Completed2 · 33%
Recruiting2 · 33%

Clinical Trials

Trial Activity

6 trials

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
Recruiting·XXenon Pharmaceuticals Inc.·Phase 3·NCT05716100·360 enrolled
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Recruiting·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 1·NCT07233239·100 enrolled
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
Completed·UCB logoUCB·Phase 2·NCT03373383·411 enrolled
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
Completed·XXenon Pharmaceuticals Inc.·Phase 3·NCT05614063·380 enrolled
A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
Terminated·UCB logoUCB·Phase 3·NCT03739840·232 enrolled
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
Terminated·UCB logoUCB·Phase 2·NCT03370120·406 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)